Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.

Abstract: A device and method for use in capturing a substance in a liquid, by feeding the liquid through a capturing device including: a lateral capillary flow matrix and a capturing matrix in fluid communication with the lateral capillary flow matrix so as to produce two lateral flows sufficient to impart transverse oscillations to the lateral flow in the capturing matrix, such oscillations driving the liquid into the interior of the capturing matrix thereby exposing its interior to the liquid.

Abstract: The present invention relates to a method of dewatering post fermentation fluids in a starch to ethanol process. More particularly the invention relates to use of a nuclease enzyme for separation of whole stillage into an insoluble fraction and a supernatant fraction. In a specific embodiment the present invention relates to a method of dewatering whole stillage comprising the steps of: i) subjecting whole stillage to one or more nuclease enzymes; ii) separating the material into an insoluble fraction and a supernatant fraction.

Abstract: Disclosed herein are system, method, and computer program product embodiments for performing a database migration with automatic privilege retention and restoration. Embodiments provide for migrating a source database object at a source database to a target database object at a target database. The embodiments provide for binding a retention tag to database objects in order to mark the objects whose privileges are to be retained during a database migration. This approach enables privileges of database objects that are involved in a database migration to be automatically restored at target database objects after the migration.

Abstract: The present invention relates to cell-based methods for screening body fluids or tissues for factors that prevent cellular uptake of lysosomal enzymes, including neutralizing factors such as neutralizing antibodies, that arise as a result of lysosomal enzyme replacement therapy.

Abstract: The present invention concerns a method for the in vitro detection of an increased risk of diabetic nephropathy in a subject suffering from diabetes and being normoalbuminuric. Another aspect of the invention pertains to a method for the in vitro identification of a marker for prediction of diabetic nephropathy. Finally, the invention concerns a kit comprising means for detecting at least two proteins selected from the group consisting of heparan sulfate proteoglycan core protein or fragments thereof, carbonic anhydrase 1, prothrombin or fragments thereof, tetranectin, CD59 glycoprotein, plasma serine protease inhibitor, mannan-binding lectin serine protease 2 or isoforms thereof, antithrombin-III, alpha-1-antitrypsin, collagen alpha-1(I) chain, alpha-enolase, histone H2B type 1-O, glutaminyl-peptide cyclotransferase, protein AMBP and zinc-alpha-2-glycoprotein.

Abstract: The present disclosure relates to methods of characterizing disease. In particular, this invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects suffering from sepsis, based on the characterization of genes associated with a reactive oxygen species (ROS) molecular signature.

Abstract: The present disclosure provides methods and systems directed to cell-free identification and/or monitoring of pregnancy-related states. A method for identifying or monitoring a presence or susceptibility of a pregnancy-related state of a subject may comprise assaying a cell-free biological sample derived from said subject to detect a set of biomarkers, and analyzing the set of biomarkers with a trained algorithm to determine the presence or susceptibility of the pregnancy-related state.

Abstract: The invention relates to a device for determining a cellular-bound analyte in a liquid sample, comprising a separation matrix with at least one indicator zone. The invention is characterized in that the indicator zone comprises a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody. The separation matrix is preferably designed in the form of the membrane of a lateral flow assay device or as a gel matrix. In a particularly preferable manner, the device comprises a membrane (2) with a charging zone (5) for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region (3) which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone (5) and the absorption region (3).

Abstract: A single-channel, chemical-immunological hybrid biosensor is disclosed. According to an embodiment, the hybrid biosensor includes a reaction strip 100 in the form of a porous membrane through which a sample 1 moves by capillary action. the reaction strip 100 is in the form of a porous membrane through which the sample 1 moves by capillary action. Biomarkers in the sample 1 are independently detected based on a chemical reaction and binding reactions on the reaction strip 100.

Abstract: Disclosed is a method for measuring phosphorylated tau protein in a biological sample collected from a subject, comprising the steps of: preparing a measurement sample containing a non-capture bead and a capture bead to which an immune complex is bound, by forming the immune complex of the phosphorylated tau protein in the biological sample, a capture antibody and a detection antibody on the capture bead, in the presence of the non-capture bead; and detecting a signal derived from the immune complex in the measurement sample.

Abstract: Contact of endothelial cells with inhibitors of inhibin and/or the alpha subunit of inhibin can be utilized to modify the activity of endothelial cell expression products including SMAD 1/5. Methods can also include inhibiting Alk1 and/or endoglin as components of inhibin-activated pathway of SMAD 1/5 signaling. Methods can be combined with other anti-angiogenesis therapies such as anti-VEGF therapies. Methods can be utilized in treatment of inhibin-expressing cancers (e.g., ovarian cancer, pancreatic cancer) as well as other pathologies such as preeclampsia and PCOS.

Abstract: A test tube including an annular body having an open proximal end and a closed distal end, and an longitudinal member in a distal portion of an interior of the annular body, the longitudinal member is substantially parallel to a central longitudinal axis of the annular body and is connected to an internal surface of the distal portion of the annular body.

Abstract: The present disclosure provides a paper-based vertical flow test platform including: a detection portion; a movable conjugation portion having an enzyme-labelled protein; and an absorbent portion. The present disclosure further provides a detection method by using the same. With the folding and sliding design, the present disclosure can reduce the volume of specimen fluids used, and prevent the interference problem. Also, a portable diagnostic test platform is provided with ease of use, lower cost, higher sensitivity and longer storage period to meet requirements of point-of-care for the fast, simple and stable detection.

Abstract: A reagent for enhancing a chemiluminescent reaction includes luminol or luminol derivatives, an oxidant, an electron mediator, and an enhancer. The enhancer is a nitrogen-containing fused heterocyclic compound having at least two nitrogen atoms. The present disclosure further provides a kit for enhancing a chemiluminescent reaction comprising the foregoing reagent.

Abstract: A method is provided for determining the presence of soluble, misfolded ?-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric ?-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded ?-synuclein aggregate is present in the biological sample.

Abstract: Provided is a color encoding method including providing a composition including a liquid medium and magnetic nanoparticles dispersed in the liquid medium; applying a magnetic field to the composition to align the magnetic nanoparticles; and applying a patterned energy source to the composition to solidify the composition, wherein more than one region of the composition are sequentially solidified with varying magnetic field strength to fix a plurality of color codes.

Abstract: This disclosure provides antigen compositions useful for diagnosing Lyme disease and for detecting antibodies that bind to Borrelia antigens. The antigenic compositions comprise a mixture of hybrid peptides and Borrelia proteins. This disclosure also provides devices, methods, and kits that are useful for diagnosing Lyme disease and for detecting anti-Borrelia antibodies in a sample to aid in the diagnosis of Lyme disease.

Abstract: Disclosed herein are caged haptens and caged hapten-antibody conjugates useful for enabling the detection of targets located proximally to each other in a sample.

Abstract: Materials and methods for detecting and treating Coccidioidomycosis (Valley Fever) are provided herein. For example, materials and methods for enriching and detecting biomarker antigens (e.g., polypeptides and/or glycans) from Coccidioides immitis and Coccidioides posadasii, the fungi that cause Valley Fever, are described herein, as are methods for treating an individual for Valley Fever based on the results of the described detection methods.

Abstract: Provided herein are chimeric polypeptides that may be used, e.g., for the diagnosis of or vaccination against Ehrlichia chaffeensis and/or Ehrlichia canis.

Abstract: A method for diagnosis of IgA nephropathy is provided using a combination of alpha-1B-glycoprotein (A1BG) or a truncated fragment thereof having a molecular weight of 13-60 kDa, orosomucoid 1 (ORMI), and Ig lambda-2 chain C regions (IGLC2) as protein markers in a urine sample from a subject.

Abstract: Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are polymerase-nanoparticle conjugates including a polymerase linked to a nanoparticle, wherein the conjugate has polymerase activity. Such conjugates can exhibit reduced aggregation and improved stochiometries wherein the average biomolecule:nanoparticle ratio approaches or equals 1:1. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing.

Abstract: Provided herein is a recombinant viral vector having packaged therein an expression cassette comprising an engineered complement regulator factor H (fH), wherein the gene encodes a hfH protein variant comprising short consensus repeats (SCRs) 1-4, 6-8, and 17-20. Pharmaceutical compositions containing this vector and plasmids comprising nucleic acid sequences that encode the fH protein variant are also provided.

Abstract: A method of monitoring an immunoassay comprises determining the shape of the flow edge of fluid across an immunoassay region. This allows, for example, early detection of possible errors in the test. The above methods may also be used to provide methods to improve the run conditions of a test during its development. The method may be applied to a competitive assay.

Abstract: Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.

Abstract: The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Borrelia antigens. The peptide compositions comprise polypeptide sequences comprising variants in the IR6 domain of the Borrelia VlsE protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Borrelia antigens and the diagnosis of Lyme disease.

Abstract: The disclosure relates to a method for quantitatively measuring concentration in an aqueous solution of a water soluble polymer that is functionalized with at least one tracer, wherein the method involves impregnating a flow assay with a test area, introducing the flow assay into a test reader, and using the test reader to compare test data to a calibration curve so as to determine the concentration of the water-soluble polymer. This method allows the determination of residuals concentration in aqueous solution recovered from different industries, including oil and gas produced water, mining fluids, industrial water systems, and water treatment applications.

Abstract: A detecting method for blood is provided. The method includes the following steps. A sensing device including a base and at least one response electrode is provided, wherein the response electrode is spaced apart from a gate end of the base. Blood including blood cells and targets is disposed on the response electrode. The blood is separated into a first part and a second part, wherein the first part is in contact with the response electrode, and the blood cell count in the first part is less than that in the second part. A voltage is applied on the response electrode, such that an electric field is generated between the response electrode and the gate end of the base, and a detection current generated from the base is measured to detect a characterize of the targets.

Abstract: The invention relates to an anti-human p53 antibody suitable for specifically binding a linear epitope which is exposed only in a conformationally altered isoform of the characteristic p53 protein of patients with Alzheimer's disease or prone to develop Alzheimer's disease or cognitive impairment during ageing. Methods and diagnostic and prognostic kits are also described.

Abstract: A system for molecular mapping includes a semiconductor substrate defining a reservoir to receive a sample of molecules and a nanofluidic channel in fluid communication with the reservoir. The system also includes a plurality of electrodes, in electrical communication with the nanofluidic channel, to electrophoretically trap the sample of molecules in the nanofluidic channel. At least one avalanche photodiode is fabricated in the semiconductor substrate and disposed within an optical near-field of the nanofluidic channel to detect fluorescence emission from at least one molecule in the sample of molecules.

Abstract: The application relates to an electrode for use in the electrochemical detection of a target species, wherein the electrode has a planar surface disposed on which are probe molecules that are capable of binding selectively to the target species, wherein the electrode, prior to binding of the probe molecules with the target species, has an electron transfer resistance per area of the electrode of from 10 megaohms cm?2 to 95 megaohms cm?2.

Abstract: A system (30) and method for detecting or predicting toxicity induced by radiation therapy. A device (34) is configured for determining polypeptide biomarkers present in a urine sample. At least one processor (36) is programmed to detect or predict radiation toxicity based on one or more polypeptide biomarkers determined to be in the urine sample.

Abstract: The present invention provides novel peptides, compositions, and methods for creating quantitative novel compositions, as well as methods for creating quantitative standards to calibrate analytes. These peptides, compositions, and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers (e.g., Tau). Also provided are kits comprising the peptides or compositions described herein, for use in assays (e.g., sandwich immunoassays).

Abstract: The present invention provides a rapid, sensitive method for forensic drug testing in a post-mortem subject or a live or a post-mortem animal using oral fluid collected from the post-mortem subject or live or post-mortem animal. The method comprises collecting a sample of oral fluid from a post-mortem subject or a live or a post-mortem animal, analyzing the oral fluid sample qualitatively to detect the presence of one or more non-naturally occurring drugs, analyzing the oral fluid sample quantitatively to determine concentration of the one or more non-naturally occurring drugs in the post-mortem subject or in the live or the post-mortem animal, and identifying the one or more non-naturally occurring drugs in the post-mortem subject or in the live or the post-mortem animal. The detection and quantification in oral fluid is more sensitive and faster than detection and quantification of the non-naturally occurring drugs in blood, urine, bile, and liver tissue collected from the same post-mortem subject.

Abstract: Described herein are methods for co-expression analysis of multiple markers in a tissue sample comprising: computing a heat map of marker expression for each of a plurality of single marker channel images, wherein each of the plurality of single marker channel images comprise a single marker; identifying one or more candidate regions of interest in each heat map of marker expression; computing overlay masks comprising the identified one or more candidate regions of interest from each heat map of marker expression; determining one or more co-localized regions of interest from the overlay masks; mapping the one or more co-localized regions of interest to a same coordinate position in each of the plurality of single marker channel images; and estimating a number of cells in at least one of the determined one or more co-localized regions of interest in each of the plurality of single marker channel images.

Abstract: A bioassay for the detection of multiple target analytes that includes living immunocytes of a plurality of predetermined types; a signal-generating reporter within each immunocyte that is responsive to predetermined changes occurring within the immunocyte and that includes a bioluminescent protein linked to a fluorescent protein; a signal transduction pathway associated with each signal-generating reporter that is operative to induce the predetermined changes within each immunocyte; a detector element associated with the signal transduction pathway that is operative to trigger the signal transduction pathway; an analyte binding element associated with the detector element that is specific to both the detector element and a target analyte; and wherein upon the binding of an analyte binding element to which a target analyte is also bound to the detector element, the detector element triggers the signal transduction pathway causing the predetermined changes to occur within the living biological cell, thereby ca

Abstract: The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

Abstract: A reagent for performing a chemiluminescent reaction includes luminol or luminol derivatives, an oxidant, an electron mediator, and an enhancer. The enhancer is a nitrogen-containing fused heterocyclic compound having at least two nitrogen atoms. The present disclosure further provides a kit for performing a chemiluminescent reaction comprising the aforesaid reagent.

Abstract: The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.

Abstract: Described herein are methods, compositions, kits and systems for multiplexed detection of target molecules from a sample. In some embodiments, the methods, compositions, kits and systems can be used to perform multiplexed protein analysis of a sample (e.g., a sample comprising a small number of cells or a single-cell sample). In some embodiments, the same sample subjected to a multiplexed protein analysis using the methods, compositions, kits and systems described herein can also be subjected to a nucleic acid (e.g., RNAs, microRNAs, and/or DNA) analysis, thereby creating an integrated expression profiling from a limited amount of sample.

Abstract: The invention relates to a method for in situ imaging of samples by cycle multiplexing that enables imaging of various molecular targets through multi-molecular read-outs on the same sample in a rapid, highly sensitive and reliable manner. The invention is further related to imaging buffers preventing the degradation of the sample and of the imaging reagents, which are particularly useful in a method of in situ imaging of samples by cycle multiplexing according to the invention.

Abstract: Provided are an organic rare-earth solid micelle, a preparation method therefor, and a method for increasing the photoelectric conversion efficiency of a solar battery. A small organic conjugated ligand is taken as a first ligand, an amphiphilic diblock polymer is taken as a second ligand, and the first ligand and the second ligand are mixed and doped with a rare-earth chloride solution, and self-assembled to form an organic rare-earth solid micelle, whereby the fluorescence emission intensity and the fluorescence efficiency of the rare-earth element are improved. Next, the prepared organic rare-earth solid micelle is spin coated on an ITO layer of a solar battery, to prepare a solar battery with the organic rare-earth solid micelle. Therefore the sunlight absorption of a cell is increased, and the photoelectric conversion efficiency is improved. The preparation process is simple, low in cost, high in photoelectric conversion efficiency, and environmentally friendly.

Abstract: Disclosed is a process and device allowing for fast measurements of the physicochemical properties of amphiphiles (lipids, surfactants, soaps, . . . ). A Marangoni flow is created and characterized using amphiphiles to be characterized. The observed flow is characterized, and using the disclosed process, one can deduce from this measurement many important physicochemical parameters of the amphiphiles such as their critical micellar concentration. Compared to existing techniques, the disclosed process offers the advantage that it requires a single experiment to deduce the parameters, when other techniques (pendant drop method, conductometry, etc . . . ) require the measurement of a quantity (interfacial tension, conductometry) against a systematically varied parameter (amphiphile concentration, . . . ). The disclosed process and devices are ideal to characterize and/or screen rapidly amphiphiles molecules based on their interaction with a solvent.

Abstract: The present invention relates to a method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto.

Abstract: Topcoat compositions are provided that are suitably applied above a photoresist composition. Preferred topcoat compositions comprise a first polymer that comprises (i) first units comprising a nitrogen-containing moiety that comprises an acid-labile group; and (ii) second units that (1) comprise one or more hydrophobic groups and (2) are distinct from the first units.

Abstract: A method for providing quality control on a lateral flow assay device or for triggering a process-related step, the device including a substrate having at least one sample receiving area, at least one reagent zone downstream and in fluid communication with the at least one sample receiving area, at least one detection zone downstream and in fluid communication with the at least one reagent zone and at least one wicking zone downstream of the at least one detection zone, each fluidly interconnected therewith along at least one fluid flow path. The detection material provided in the at least one reagent zone produces a detectable signal that can be tracked and monitored prior to the completion of at least one test being performed on the lateral flow assay device.

Abstract: Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits.

Abstract: The present invention relates to anti-PD-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have CDRs as provided in the enclosed sequences. Also part of the invention are nucleic acids encoding these antibodies, expression vectors comprising such nucleotide sequences and host cells that comprise said nucleotide sequences or expression vectors.

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.